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ABSTRACT 
 
 
 The party drug 3,4-methylenedioxymethamphetamine -better known as MDMA or 
ecstasy- has numerous effects on the human body, characterized by a rush of energy, euphoria 
and empathy. However, also a multitude of toxic/neurotoxic effects have been ascribed to 
MDMA, based upon case reports and studies in animals. Given the intrinsic difficulties 
associated with controlled studies in human beings, most of our insights into the biology of 
MDMA have been gained through animal studies. The vast majority of these studies utilizes a 
pharmacological approach to elucidate the mechanisms by which MDMA exerts its effects. 
Advances in genetics during the last decade have led to the development of several mouse 
models (transgenic or knockout) that have greatly contributed to our understanding of MDMA 
biology. This review provides an overview of these genetically modified animal models, in 
the light of some characteristic effects of MDMA, e.g. hyperlocomotion, neurotoxicity, 
hyperthermia, behaviour or rewarding. Without a shadow of a doubt, the next decade will 
bring many more advanced animal models, such as mice with site-specific deletion or rescue 
of genes and more genetically modified rat models. These models will further improve our 
knowledge on the pharmacology and toxicity of MDMA and, possibly, may assist in 
developing therapies coping with potential damage in abusers of MDMA and other drugs, as 
well as in patients suffering from specific neuronal pathologies. 
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I. Introduction 
 
 In the late 1980s, the psychoactive recreational drug ecstasy was associated with the rave culture and, 
since the 1990s, became more widely available in many dance clubs and other venues. Still now, ecstasy is most 
often consumed by youngsters during the weekend at techno and rave dance parties [1]. Whereas in past years, 
ecstasy tablets may have had singularly, or in combination, MDMA (3,4-methylenedioxymethylamphetamine), 
MDEA (3,4-methylenedioxyethylamphetamine) or MDA (3,4-methylenedioxyamphetamine) as the major 
psychoactive constituents, the majority of more recently seized tablets sold as ecstasy do contain MDMA as the 
primary psychoactive component [2]. 
 The unique pharmacological properties of MDMA result in behavioural effects that are distinct from 
those of both phenylalkylamine psychostimulants and classical hallucinogens (as described by L. Schmued in 
detail in this issue). Typically, the mood enhancing properties of MDMA are summarized in the 3 E’s: Energy, 
Empathy and Euphoria, which are pretty well reflected by the name under which it was originally (and still is) 
“marketed”: Ecstasy. In addition, these effects are often accompanied by post-drug anxiety and agitation [3]. The 
pharmacology of MDMA is distinct from that of amphetamines and other stimulants (e.g. cocaine) in the fact 
that it not only produces an increase in drive and energy (encouraging and allowing users to dance for long 
periods), but also a sense of warmth and empathy with others, and therefore it is also referred to as an 
‘empathogen’ or ‘entactogen’ [1, 4]. At the cellular level, MDMA acts by influencing the balance of monoamine 
neurotransmitters in the brain, with as main action a disturbance of the homeostasis of serotonin (5-
hydroxytryptamine, 5-HT) and dopamine (reviewed by L. Schmued elsewhere in this issue). 5-HT is a 
modulatory neurotransmitter that acts throughout the brain and has been shown to play a role in a number of 
behaviours, including sleep, appetite, thermoregulation, reward, locomotion and mood. A prime effect of 
MDMA is the release of 5-HT from presynaptic nerve terminals, which then may act on nearby 5-HT receptors. 
Central in this effect is the modulation by MDMA of a major regulator of synaptic availability, the 5-HT 
transporter (5-HTT). This transporter is the prime target of most antidepressant and anxiolytic drugs, being 
(selective) serotonin reuptake inhibitors, ((S)SRIs) [5]. In fact, the basis for the involvement of 5-HTT in 
MDMA neurotoxicity was laid by showing that antidepressants like fluoxetine or fluvoxamine could prevent 
serotonergic neurotoxicity in rats [6-8]. Thus, MDMA can be described as an indirect agonist at most 5-HT 
receptors. Its empathogenic properties are thought to be due to the release of 5-HT in the brain, of which MDMA 
causes the release to a much greater extent than other psychostimulants (such as cocaine or amphetamine) [9, 10]. 
In addition to its indirect effect at 5-HT receptors, MDMA may also exert some effects by acting directly at 5-
HT receptors [11]. More specifically, its action at 5HT2A receptors has been associated with its hallucinogenic 
properties [9, 10]. Similar to other psychostimulants, MDMA treatment also results in release of the 
neurotransmitter dopamine, this release being more prominent at higher doses, though still remaining less 
pronounced when compared to other psychostimulants. 
 The majority of users consider their use of ecstasy as ‘recreational’, rather than viewing it as a drug for 
daily or dependent use [12-14]. Based upon data from users and presentations to emergency departments, it is 
clear that ecstasy users frequently also use other drugs and even combine ecstasy intake with the intake of 
alcohol, nicotine/tobacco, cannabis, ketamine, gamma-hydroxy butyric acid (GHB), cocaine or amphetamine 
[15-19]. In addition, pills sold as ecstasy do not only show a huge spread in the amount of MDMA being present, 
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but may contain other substances instead or in addition [2]. As a consequence, it is often difficult to attribute 
(toxic) effects in ‘real-life’ cases solely to ecstasy [20]. Irrespective of the debate about how harmful ecstasy 
exactly is [21], it is a fact that there is a wealth of literature available supporting the harmful effects that have 
been associated with the intake of MDMA [8]. These can be divided into the indirect effects, which are 
associated with behaviours in which the users may engage, such as risk-taking or prolonged energetic raving, 
and the direct toxic effects, especially seen at higher doses. The latter may range from relatively mild or subtle 
(e.g. vomiting, nausea, headache and impaired cognitive function) to potential life-threatening (e.g. 
cardiovascular collapse, severe hyperthermia, multi-organ failure) and from acute to long-term (related to 
neurotoxicity) (reviewed by [8]). Tolerance to some of the psychological actions of MDMA has been reported in 
some human users of high doses of the drug [22], which may result in taking even higher (more toxic) doses to 
get the desired effect. Important to note, however, is that adverse effects of MDMA are not restricted to high-
dose-induced neurotoxicity. Studies in mice and rats have shown that low doses, which did not cause traceable 
neurotoxicity, could also induce deficits in e.g. learning and cognitive function (see further). Several contributing 
factors have been put forward with respect to the (neuro)toxic responses induced by MDMA, including, amongst 
others, hyperthermia and metabolisation (of both MDMA and neurotransmitters) [8]. Given the non-linear 
pharmacokinetics of MDMA, it is difficult -or even almost impossible- to make a direct correlation between its 
plasma concentration and its (toxic) effects [23]. In addition, oxidative metabolisation of MDMA gives rise to 
products with higher toxicity than MDMA itself. This implies that the rate of generation and/or elimination of 
these metabolites -which differs between and even within species- may determine the severity of the toxic effects. 
Despite the fact that there is more compelling evidence for MDMA-induced neurotoxicity in rodents than in 
humans, it is unlikely that the human brain is less sensitive than the rodent brain to a neurotoxic insult [8]. The 
scientific literature about MDMA intoxications provides a heterogeneous picture, with multiple case reports, 
detailing primarily acute complications -including death- and showing a wide range of plasma and tissue 
concentrations (reviewed by E.A. De Letter et al. elsewhere in this issue). Given the inherent limitations of 
observations made in ‘real-life’ ecstasy users and given the relatively limited availability of clinical studies in 
humans, most of our knowledge on the mechanisms of action of MDMA has been gathered from studies on 
animals. Most of these studies have been conducted in rats and mice, although also e.g. rabbits, dogs and non-
human primates have been used. Since it is impossible to cover all these studies within this review, we will focus 
here especially on studies using genetically modified mice. For more detailed information on other animal 
studies and the other aspects of MDMA, the reader is referred to other reviews in this special issue, as well as to 
the recent extensive in-depth review by Capela et al. on the molecular and cellular mechanisms of ecstasy-
induced neurotoxicity [8]. 
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II. Essentials from studies performed in (genetically modified) rodents 
 
 The majority of our insights about the action of MDMA has been gained by the administration of 
pharmacological agents (e.g. agonists or antagonists at certain receptors) and by evaluating whether these had an 
impact on a certain effect of MDMA. Although the value of these studies should not be underestimated, these 
studies inherently suffer from some major drawbacks. First of all, most (if not all) pharmacological agents only 
have a limited specificity, which often makes it difficult to draw definitive conclusions about the implication of a 
specific receptor subtype in a given effect. Second, these pharmacological agents have an impact on the 
organism as a whole, which may render it difficult to discriminate between effects or effectors. Typical examples 
include pharmacological agents, which, in addition to their effect on the brain, may also influence MDMA 
metabolism in the liver or which, as such, already have an impact on body temperature. 
 Recently, multiple studies with genetically modified mice -transgenic or knockout (KO)- have 
complemented the studies with pharmacological agents and have thus improved our biological insight into the 
action of MDMA. Obviously, also in these studies, several limitations have to be kept in mind [24]. First, and 
most importantly, differences between animals (more specifically mice) and humans usually hamper some 
conclusions. Second, administration in the vast majority of these studies was by intraperitoneal injection of high 
dosages, which may not only lead to a difference in kinetics, but may as well result in a different profile of (toxic) 
metabolites. Although this acute administration differs substantially from the human situation, in which -
predominantly oral- use may extend over weeks, months, or even years, it may be related to the final outcome, 
being neurotoxicity. Third, whereas several research groups have used racemic mixtures (better resembling the 
‘real-life’ situation), others have used S(+)-MDMA, which is a more potent releaser of monoamines and was 
shown to have higher neurotoxicity. Fourth, strain differences may be an underlying cause of (at least) some 
conflicting findings, with different strains showing different sensitivities to (the toxic effects of) MDMA. Fifth, 
pharmacokinetics (including metabolism) and pharmacodynamics may differ substantially between different 
(and even within the same) species, which is of high relevance given the potential (toxic) effects of metabolites. 
Lastly, specifically holding true for genetically modified organisms, one has to bear in mind that developmental 
adaptations and/or redundancy (compensation by other proteins) may complicate the interpretation. With respect 
to this, genetically modified mice may be regarded sometimes as models of a disease state rather than as 
pharmacological models. 
 In addition to the limitations associated with projecting animal studies to humans, the complex 
neurochemical profile induced by MDMA has to be taken into account, with reported increases in the synaptic 
concentrations of 5-HT, dopamine, but also of norepinephrine, gamma-amino butyric acid (GABA) and 
acetylcholine [8]. The foremost important target of MDMA is the 5-HT system, which readily can be deduced 
from its higher affinity for the 5-HT transporter (5-HTT) than for the dopamine transporter (DAT) and from its 
ability to induce a more potent release of 5-HT than of dopamine [25-27]. Yet, also the dopamine and other 
systems have been shown to play a role (from modulatory to prominent) in certain effects of MDMA. In this 
context it should also be emphasized that several effects, such as drug reward, are typically the result of 
mechanisms that are inherently polygenic and involve the action of multiple neurotransmitters, acting to a 
different degree, depending on the circumstances [28]. Referring to all the above-mentioned possible 
confounding factors and the complex profile induced by MDMA, in addition, it should be kept in mind that mice 
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as such already differ substantially from other species regarding the pattern of MDMA-induced neurotoxicity. 
While rats and non-human primates (as well as humans) show primarily serotonergic neurotoxicity, 
dopaminergic neurotoxicity is also observed in mice [29, 30]. In the following section, an overview will be given 
of different models (primarily murine) that have been used to study many of the above-mentioned (toxic) effects 
of MDMA. As readily mentioned above, this review primarily aims at providing an overview of studies using 
genetically modified mice, rather than covering all described effects of MDMA. Although obviously all the 
effects of MDMA are inherently interconnected, the following sections have been organized arbitrarily 
according to several prototypical aspects of MDMA that have been investigated in these studies, including e.g. 
hyperlocomotion, hyperthermia, neurotoxicity or rewarding.  
 
II.1. Pharmacokinetics and pharmacodynamics 
 In humans and rats, the main metabolisation of MDMA occurs in liver, with a prominent role for 
CYP2D6 (orthologous to CYP2D1 in rat strains) [23, 31]. Although not genetically modified per se, the dark 
agouti rat strain, which lacks this enzyme, may mimic a ‘poor metaboliser’ in humans. MDMA administration to 
this strain leads to higher MDMA brain concentrations [32]. In addition, MDMA is known to auto-inhibit its 
metabolism, which explains its non-linear kinetics, exemplified by the fact that following high doses or after a 
second dose shortly after a first one, plasma concentrations increase disproportionally [23, 33, 34]. Despite these 
observations, no convincing link could be shown thus far between CYP2D6 genotype and MDMA intoxications 
[35-37]. This lack of association may be related to the nature of the metabolites, which have a higher 
(neuro)toxic potential than MDMA itself [38, 39]. Thus, metabolism of MDMA can be considered as a double-
edged sword: a slower metabolism results in higher MDMA plasma concentrations, whereas faster metabolism 
results in a higher formation of toxic metabolites.  
 Phosphoglycoproteins  (P-gps), encoded by a family of multidrug-resistant genes (MDR1 and MDR3 in 
humans and mdr1a, mdr1b and mdr2 in mice), function by transporting molecules across membranes (including 
the blood-brain barrier) by acting as ATP-dependent drug efflux pumps [40]. In doing so, they provide cells with 
drug resistance, which may be favourable, but at the same time may impose problems with respect to therapeutic 
drugs. Mice defective in MDR1a have been used to study the role of P-glycoproteins in the neurotoxicity of 
certain drugs, including methamphetamine and MDMA [41]. While for methamphetamine there is evidence that 
the presence of MDR1a may provide protection against depletion of dopamine and dopamine transporters, the 
effects of MDMA are not inhibited in mdr1a -/- mice. A certain facilitation of MDMA passage through the 
blood-brain barrier in the presence of MDR1a in wild-type (wt) mice was even observed, with mdr1a -/- mice 
being more resistant to MDMA-induced reductions in dopamine and dopamine transporter expression, at least at 
certain dosages (5-10 mg/kg) [41]. This result, based upon an evaluation 1 week post-dose, suggests that MDR1a 
could be considered as a potential target for MDMA abuse treatment, since a candidate drug inhibiting MDR1a 
might limit MDMA’s acute and neurotoxic effects. However, arguing against an important role for MDR1a were 
the findings by Upreti and Eddington, showing that mdr1a wt and -/- mice did not show significant differences in 
brain concentration of MDMA or its active metabolite MDA 0.5 and 4h following a 5 mg/kg i.p. injection of 
MDMA [42]. Finally, Scheidweiler and colleagues, administering 10 to 40 mg/kg to mdr1a wt or -/- mice found 
differences in dihydroxyphenyl acetic acid (DOPAC) / dopamine ratios in striatal specimens from treated mice, 
which depended on the time point of evaluation and the dosage applied [43]. Also here, striatal concentrations of 
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MDMA and its metabolite MDA were not higher in wt than in mdr1a -/- mice, suggesting that altered MDR1a-
mediated transport of MDMA does not account for the observed differences of MDMA’s effects on 
DOPAC/dopamine ratios between mdr1a +/+ and -/- mice. Alternative mechanisms or compensatory changes in 
protein expression/activity in mdr1a -/-mice could account for the observed inter-strain differences on dopamine 
turnover. 
 
II.2. Hyperlocomotion 
 Similar to its energetic effect in humans, MDMA induces hyperlocomotion when administered to rats or 
mice. The mechanisms underlying this MDMA-induced hyperactivity have been the subject of multiple studies, 
which have applied a wide variety of genetically modified mice, pointing at the involvement of many different 
systems. 
 
II.2.1. The serotonergic and closely related systems 
 MDMA effects on locomotor activity are primarily mediated by serotonergic activation. Low dosage (3-
10 mg/kg) MDMA-induced hyperactivity in mice is (virtually) completely blocked by deletion of the genes for 
either the 5-HT1B receptor [44, 45], the 5-HT2B receptor [46] or the 5-HT transporter (5-HTT) [47]. With respect 
to the involvement of other 5-HT receptors in MDMA-induced hyperlocomotion, rat studies have suggested a 
lack of involvement of the 5-HT1AR [48], while the 5-HT2A and the 5-HT2C receptor may have a facilitary and 
inhibitory influence, respectively [49]. In contrast to wt mice, 5-HT2BR -/- mice do not show increased 
extracellular levels of 5-HT or dopamine following a 10 mg/kg dosage of MDMA [46]. In addition, the uptake 
activity of the 5-HT and dopamine transporters were unaltered in these mice, suggesting that the 5-HTT-
dependent release of 5-HT requires the presence of a functional 5-HT2BR. MDMA has been shown to require 5-
HTT for releasing 5-HT [50, 51]. Indeed, 5-HTT -/- mice, which readily have higher extracellular 5-HT levels in 
the prefrontal cortex than wt controls, did not show a further increase following MDMA stimulation (10 mg/kg). 
These mice lack the locomotor-stimulating effects of MDMA, with an intermediate effect seen in 5-HTT +/- 
mice [47]. In contrast, amphetamine-induced (i.e. dopaminergic) hyperlocomotion is maintained in the 5-HTT -/- 
mice. Apart from the dopaminergic system, described further, several other receptor systems appear to be 
modulating the 5-HT-dependent MDMA-induced hyperlocomotion. 
- Compan and colleagues [52], using 5-HT1BR KO mice, have suggested a role for enkephalins in 
MDMA’s locomotor effects. They found that, 3 hours following a 10 mg/kg challenge, 129/Sv wt, but 
not KO mice, showed less enkephalin immunoreactivity in the globus pallidus, likely reflecting 
increased enkephalin release. This finding of increased 5-HT1BR-mediated enkephalin release, together 
with the failure of MDMA to promote hyperactivity when combined with naloxone, led them to suggest 
a role for opioid signalling in MDMA-induced hyperlocomotion. 
- Also the cannabinoid receptor system has been shown to modulate several pharmacological responses 
following acute MDMA administration. Whereas MDMA-treated cannabinoid receptor (CB1R) wt 
mice show increased locomotor activity, elevated body temperature, and anxiogenic-like (open field 
avoidance) responses, these responses are all less pronounced or even absent in CB1R -/- mice. These 
results are likely related to the impaired serotonergic negative feedback in CB1R -/- animals, which 
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under basal conditions readily show elevated extracellular 5-HT and reduced 5-HTT in brain areas like 
the prefrontal cortex [53]. 
- The MDMA-induced increase in locomotion, observed in wt mice, was less pronounced in histamine 
H3 receptor (H3R) -/- mice, pointing to a functional interaction between histaminergic and serotonergic 
neurons which modulates the locomotor effects of MDMA [54]. 
Higher dosages of MDMA (30 mg/kg) did induce hyperactivity in both 5-HT1BR KO 129/Sv and HT2BR KO 129 
Sv/PAS mice [55]. Sensitization to the locomotor-stimulating effects of MDMA, which was investigated in the 
5-HT2BR KO model, was absent at low-dose, but present at high-dose MDMA. The occurrence of locomotor 
stimulation (and sensitization) at high doses of MDMA, in the absence of HT1BR or HT2BR, might be owing to a 
delayed increase in dopamine release. Indeed, while administration of 30 mg/kg to 5-HT2BR -/- mice still didn’t 
elevate extracellular 5-HT in the nucleus accumbens, extracellular dopamine levels did show an increase [55]. 
This suggests that the high-dosage MDMA-induced 5-HT release requires the presence of a functional 5-HT2BR, 
while MDMA-induced dopamine release appears to be partially independent of the 5-HT2BR. This dopamine 
release may thus explain the hyperlocomotion and locomotor sensitization observed at high doses of MDMA in 
5-HT2BR -/- mice. 
 
II.2.2. The nNOS system 
 Sensitization to the locomotor-stimulating effect of MDMA has also been evaluated in mice lacking 
neural NO synthase (nNOS -/-) [56]. These mice lack a locomotor response following a 5-day challenge with 
methamphetamine, but, in contrast, do not show a reduction in MDMA-induced hyperlocomotion following a 5-
day challenge with 10 mg/kg MDMA [56], showing that nNOS is not required for MDMA-induced 
hyperlocomotion. Although these mice initially showed sensitization (with progressively higher locomotor 
activity during the 5-day challenge period), this sensitization towards MDMA-induced hyperlocomotion was no 
longer apparent when the mice were challenged 40 days later. This suggests that, whereas the induction of 
sensitization may primarily involve (nNOS-independent) 5-HT neurotransmission, the persistence of 
sensitization may depend on an intact nNOS system, possibly modulating dopamine neurotransmission.  
 
II.2.3. The dopaminergic system 
 Well-defined tests for locomotor activity and locomotor patterns offer the possibility of scoring more 
subtle changes in behaviour, induced by psychostimulants, making it possible to score the qualitative aspect of 
the MDMA-induced locomotion. Using such systems, MDMA has been shown to induce locomotor activity 
(increased path length), with as peculiarities, increased path linearity (better predictable, straight paths) and 
increased repetition of specific paths (stereotypy; perseverative thigmotaxis), with mice typically running in 
straight lines around the periphery of an open test field. As discussed above, several studies have shown a 
prominent role for the 5-HT system in the hyperlocomotory effects of MDMA. This is exemplified by 5-HT1BR -
/- mice treated with 30 mg/kg MDMA, in which the stereotypical aspect of hyperlocomotion was less than or 
equal to wt mice: MDMA-treated KO mice enter the open field more and have more curves and turns in their 
paths [45]. However, different studies using pharmacological agents have also shown that the dopamine receptor 
system is implicated in MDMA-induced locomotion and motor patterns, especially at higher doses. The precise 
involvement of dopamine receptors in this effect has been evaluated in wt, dopamine D1, D2 and D3 receptor 
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KO C57BL/6J mice that had been treated with MDMA [57]. Overall, gene deletion of D1, D2 or D3 has only 
moderate effects on MDMA-induced hyperlocomotion, highlighting the importance of non-dopaminergic 
systems for the effect of MDMA on locomotor activity. In general, modulation of the effect of a 20 mg/kg 
dosage of MDMA in these KO mice only became apparent at a later stage of the testing phase (40 min post-
injection). This is in line with the observation that in 5-HT1BR KO mice, which are refractory to MDMA 
hyperlocomotion at low dosages, administration of high MDMA dosages does result in a delayed hyperactivity 
[45]. More specifically, D1 and D2 KO mice exhibited respectively greater and reduced MDMA-induced 
hyperactivity (path length), as compared to wt mice. Of note are the differences seen in the MDMA-induced 
locomotory patterns in these mice: whereas D1 KO mice showed an increase in linear paths, D2 KO mice lacked 
the typical repetitivity in their paths, as compared to wt mice. Changes in D3 KO mice were less pronounced, 
although female (but not male) D3 KO mice displayed slightly reduced MDMA-initiated hyperlocomotion [57]. 
Similar to the serotonergic system, where the 5-HT transporter (5-HTT) is a major regulator, the intensity and 
duration of dopamine signalling is under the major control of the dopamine transporter (DAT). Mice with a DAT 
(Slc6A3) gene deletion exhibit a chronic hyperdopaminergic state, presenting with a hyperactive phenotype, 
characterized by locomotor hyperactivity and a perseverative, stereotypical locomotor pattern at the periphery of 
an open field [58-60]. In fact, this phenotype resembles the one seen upon treatment of wt mice with MDMA. 
Paradoxically, despite the fact that MDMA increased locomotor activity in wt mice, it attenuated locomotor 
hyperactivity in DAT -/- mice [61]. This paradoxical calming effect is similar to the one observed following 
treatment of DAT -/- mice with other psychostimulants, which has been shown to involve serotonergic 
neurotransmission [59]. Likely, the treatment of DAT -/- mice with psychostimulants results in partial restoration 
of a correct balance between serotonergic and dopaminergic neurotransmission. This balance, which is required 
for normal motor activity, is disrupted in both non-treated DAT -/- mice and in wt mice following treatment with 
MDMA. Contrasting with its attenuation of hyperactivity in DAT -/- mice, is the potentiation by MDMA of 
other discordant behaviours of these mice. Following treatment with MDMA, DAT -/- mice showed exaggerated 
locomotor stereotypy (as evidenced by the occurrence of highly predictable, very straight paths and the 
avoidance of entering the central area of a testing chamber). The contrasting effects of MDMA on locomotor 
hyperactivity and locomotor diversity of DAT -/- mice indicate that different mechanisms underlie these effects. 
This is in line with i) the distinct phenotype that was observed in MDMA-treated D1 and D2 receptor KO mice 
(mentioned above) [57] and with ii) the finding that both D1 and D2 antagonists reduced locomotor 
hyperactivity in DAT -/- mice, whereas only the D1 antagonist normalized the MDMA-induced perseverative, 
stereotypical patterns [60]. The DAT -/- mice have also been used to generate an acute mouse model of 
Parkinson disease [62]. DAT -/- mice have elevated extracellular dopamine and highly decreased intracellular 
dopamine stores, which renders them very dependent on the ongoing synthesis of dopamine. As a consequence, 
pharmacological blockade of dopamine synthesis results in acute severe dopamine depletion, accompanied by 
the transient appearance of Parkinson disease symptoms (e.g. akinesia, rigidity, body tremor, ptosis (droopy 
eyelids)). Remarkably, the compound found to be most effective in inducing forward locomotion and in 
counteracting akinesia and rigidity in DDD (dopamine-depleted DAT -/-) mice was MDMA (at high doses). This 
indicates that MDMA can affect movement control in a dopamine-independent manner. A similar “anti-
parkinsonian” effect has been observed in rats, in which MDMA counteracted haloperidol-induced parkinsonism 
[63]. 
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II.3. 2eurotoxicity 
II.3.1. Models focusing on serotonergic and dopaminergic systems 
 As readily mentioned above, it remains a challenge to directly compare the neurotoxicity of MDMA in 
animals and humans, given the differences that exist between animals (especially rodents) and humans in terms 
of the pattern of drug exposure (administration vs. abuse) and of the mechanisms and assessments of 
neurotoxicity [24]. Nevertheless, there is now plenty of evidence demonstrating the neurotoxicity of MDMA to 
dopaminergic and serotonergic neurons in rodents and its potential to cause cognitive impairments in humans [8]. 
The neurotoxic effects of MDMA are typically studied using administration of high dosages of MDMA and/or 
repeated administration (“binge” treatment) to animals, reflecting to some extent the repeated exposure to high 
doses of MDMA in heavy users. As readily mentioned above, this approach has obvious limitations, but 
nevertheless may provide useful information on the neurotoxicity exerted by MDMA. Delayed (i.e. being 
considered as neurotoxic) effects of sub-chronic MDMA on the 5-HT system were studied by Renoir et al., 
evaluating wt and 5-HTT -/- C57Bl/6J mice, 4 weeks after a 20 mg/kg dosage regimen of MDMA (administered 
twice daily during 4 days) [64]. Evaluation of the firing rate of dorsal raphe nucleus serotonergic neurons 
indicated a significantly lower firing rate in MDMA-treated wt but not 5-HTT -/- mice. In MDMA-treated wt 
mice this effect was linked to an apparent hypersensitivity of the inhibitory 5-HT1AR and to a decrease of 5-HT 
levels in most brain areas. Consistent with other studies [65-68], this delayed limited (though significantly) lower 
5-HT tone in the brain of MDMA-treated wt mice was linked to a decreased hippocampal cell proliferation and a 
depressive-like behaviour. The latter was evidenced by an increase in immobility of MDMA-treated wt mice in a 
forced swim test, whereas the already higher immobility in 5-HTT -/- mice did not further increase following 
sub-chronic exposure to MDMA. These findings support the fact that MDMA, via its persistent negative effects 
on the 5-HT system, may contribute to the mood and cognitive disorders observed in MDMA users. The fact that 
also the neurotoxic effects that were observed in wt mice were abolished in 5-HTT -/- mice, lends support to an 
important role for this transporter in the mechanism of MDMA neurotoxicity, possibly via mediating entry of 
MDMA and its metabolites into 5-HT nerve terminals. As mentioned above, neurotoxicity in mice is -dependent 
on the strain and the conditions used- considerably dopaminergic. In particular, mice develop long-lasting 
dopamine axon terminal damage, with dopamine cell bodies remaining intact [8, 29]. Consistent with the 
importance of the dopaminergic toxicity of MDMA in mice is the observation that DAT -/- mice are resistant to 
the neurotoxic effects of MDMA. Indeed, evaluation seven days after application of a neurotoxic regimen of 
MDMA (4x 20mg/kg, every 2h) showed that DAT -/- mice were refractory to the neurotoxic potential of 
MDMA, while all wt mice had succumbed [62]. Using cDNA microarray technology, Xie et al. identified 
metallothionein-I and -II as two proteins whose expression appeared to be linked to MDMA-induced toxicity at 
dopamine neurons [69]. Metallothioneins are cysteine-rich, low molecular weight, heavy metal (i.e. zinc) 
binding proteins that have been postulated to detoxify metals; to play a role in homeostasis of processes or 
proteins requiring zinc; and to be neuroprotective (e.g. by protecting against reactive oxygen species). Their 
expression is induced in the central nervous system in response to practically any harmful challenge. Double 
Mt1/Mt2 -/- mice have been described to be more sensitive to toxic metals and oxidative stress [70, 71]. 
Likewise, these animals were more sensitive to MDMA’s neurotoxic effects, as evidenced by larger dopamine 
deficits 1 week after a neurotoxic regimen of MDMA, with no significant depletion of 5-HT and no significant 
differences in MDMA-induced hyperthermia [69]. This effect may be related to an inability of these animals to 
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cope with the higher oxidative stress which is imposed on them following MDMA treatment. Conversely, both 
zinc administration to wt mice, which increases metallothionein expression, and administration of 
metallothionein-I and -II protein, provided (partial) protection against MDMA-induced dopamine deficits. In 
conclusion, these mice may serve as a model system with increased sensitivity to the neurotoxic (dopaminergic) 
effects of MDMA. 
 Swiss Webster mice were shown to serve as a possible model of selective dopamine and 5-HT 
neurotoxicity following stimulation with appropriate doses of different psychostimulants [72]. In contrast to 
methamphetamine and fenfluramine, which respectively affect the dopaminergic and serotonergic system in 
these mice, MDMA administration to these mice results in a marked depletion of both dopamine and DAT 
binding sites and of 5-HT and 5-HTT binding sites. The dual dopaminergic/serotonergic depletion by MDMA in 
these mice may serve as a useful model for a similar depletion that may develop in humans abusing both 
methamphetamine and MDMA. 
 
II.3.2. Models focusing on metabolism and oxidative damage 
 Support for a role of oxygen-based radicals in MDMA-induced neurotoxicity came from studies by 
Cadet et al., using transgenic mice carrying the complete sequence of the human copper-zinc superoxide 
dismutase (CuZnSOD) gene [73, 74]. This mouse model was used to assess lethal, subacute and long-term 
effects of MDMA. In contrast to wt mice, homozygous CuZnSOD transgenic mice showed resistance to the 
lethal effects of MDMA and did not show depletion of striatal DA or DOPAC 24 h or 2 weeks following single 
or multiple (3 x every 24 h) injection with MDMA (50 mg/kg). The resistance against lethality was smaller in 
heterozygous CuZnSOD mice, which also showed DA depletion at the 24 h time point following a single 
injection and small decreases in DA levels following multiple injections. These findings suggest that both the 
acute lethal and the subacute and long-term effects of MDMA involve the intracellular overproduction of 
superoxide radicals. In a follow up study by the same group [75], they found that administration of MDMA (4 x 
20 mg/kg) to CD-1 wt mice caused marked decreases in CuZnSOD activity in the frontal cortex, caudate-
putamen and hippocampus, along with decreased catalase and glutathione peroxidase activity and increased lipid 
peroxidation. These altered enzyme activities were not observed in homozygous CuZnSOD mice. In summary, 
these data suggest that CuZnSOD overexpression could protect mice against MDMA-induced overproduction of 
free radicals, both direct and indirect, via inhibiting the perturbation of antioxidant enzymes. 
 Several reports have described the formation of reactive oxygen species (ROS) in the brain of MDMA-
treated animals [8, 29, 76, 77]. Superoxide radicals may react with NO, formed through the action of NO 
synthases such as neural NO synthase (nNOS), resulting in the formation of the highly reactive neurotoxin 
peroxynitrite (ONOO
-
). Dopaminergic neurotoxicity, induced by high doses of psychostimulants, such as 
methamphetamine, was shown to be abrogated in mice deficient in neuronal nitric oxide synthase (nNOS -/-) 
[78]. However, as no difference in depletion of 5-HT in wt and nNOS KO mice was observed following a high-
dose regimen of MDMA, this suggests that nNOS does not play a role in this effect of MDMA [56]. Remarkably, 
this high-dose regimen still lowered striatal dopamine levels in nNOS -/-, while DAT binding sites remained 
unaffected. This discrepant finding might be related to the occurrence of dopamine toxicity, secondary to 5-HT 
neurotoxicity. 
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 Monoamine oxidases (MAO) are enzymes, bound to the outer membrane of mitochondria, which 
catalyze the oxidation of monoamines, such as 5-HT, dopamine or norepinephrin [79]. While a central role for 
MAO-A in the metabolism of endogenous monoamines such as norepinephrin, dopamine and 5-HT is well-
established, MAO-B, at least in basal conditions, does not seem to play a major role in monoamine metabolism 
[80, 81]. An opposite role for MAO-B in MDMA-induced dopamine and 5-HT depletion can be deduced from 
the study of Fornai et al. [82]. Using high-dose (2x 50 mg/kg) MDMA treatment of MAO-B deficient mice and 
evaluation one week later, these authors found that, as compared to wt mice, 5-HT depletion does not occur in 
these mice, while dopamine loss was unaffected or became even more pronounced in MAO-B knockouts. On the 
one hand this may be related to a reduced formation of MAO-B-generated toxic dopamine metabolites in 
serotonergic neurons, while, on the other hand increased formation of toxic dopamine metabolites may take 
place in dopaminergic neurons, where also MAO-A may be less functional because of inhibition by MDMA [83]. 
 
II.4. Hyperthermia 
 Hyperthermia, which is often fatal when extreme, is the most prominent adverse reaction clinically 
assessed in human MDMA intoxications. Hyperthermia following MDMA administration has been observed in a 
wide variety of species, from mice, rats, pigs and non-human primates to human beings [84]. However, at least 
in some species, this acute dose-dependent rise in body temperature was shown to be dependent on the 
environmental temperature. Studies on rodents have demonstrated hypothermia in rats and mice following 
MDMA administration at lower temperatures [85, 86]. This hypothermia, following MDMA exposure at lower 
ambient temperatures, does not occur in humans and primates. Hyperthermia in humans typically occurs when 
MDMA is used in the setting of “dance parties”, in which factors such as crowdedness, high activity, high 
ambient temperature and dehydration exacerbate the otherwise mild hyperthermic effect (temperature rise up to 
0.4°C) of MDMA seen under laboratory conditions [34]. As a result, excessive and potential life-threatening 
hyperthermia (body temperature up to 43°C) may occur in humans. Obviously, under laboratory conditions it is 
difficult to mimic this requirement of a ‘proper’ setting for the hyperthermic action of MDMA. Using a wide 
variety of in vivo and in vitro approaches, multiple studies have demonstrated the participation of multiple 
receptor pathways in the hyperthermic action of MDMA. These include the 5-HT2A receptor (for which MDMA 
may serve as a direct agonist [11]), the Dopamine D1 receptor and the adrenergic receptor (α1 subtypes) [8]. 
Several genetically modified mouse models have been used to study the hyperthermic effects of MDMA. 
- The cannabinoid receptor signalling system, which is, as mentioned above, linked to the serotonergic 
system, has been implicated by Touriño et al. in modulation of the hyperthermic response [87]. These 
authors demonstrated that the elevation of body temperature following the administration of MDMA to 
cannabinoid receptor CB1R -/- mice was significantly lower than in wt animals. 
- MDMA has been shown to have affinity for α2 adrenoreceptors (ARs) and MDMA treatment of rats 
results in activation of ARs [11, 88, 89]. A remarkable effect on body temperature was seen upon 
MDMA treatment of α2AAR -/- mice: whereas MDMA (20 mg/kg) resulted in hyperthermia in wt mice, 
these KO mice showed a biphasic response, with initial hypothermia followed by hyperthermia [90]. 
Support for the specificity of this peculiar finding came from the fact that a similar observation, though 
less pronounced, was made in MDMA-treated wt mice that had been pre-treated with a rather selective 
α2A adrenoreceptor antagonist. An important role for centrally released norepinephrin in MDMA-
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mediated thermogenesis, acting via a double-edged sword of heat generation, was proposed by Mills et 
al. [91]. On the one hand, increased norepinephrin plasma levels may lead to a loss of heat dissipation 
through α1AR-mediated vasoconstriction, while stimulation of α1 and β3 adrenergic receptors may 
regulate a mitochondrial protein in skeletal muscle, uncoupling protein-3 (UCP-3). Mitochondrial UCPs 
act by “uncoupling” free energy stored in the mitochondrial electrochemical proton gradient from ATP 
synthesis by regulating an inducible, thermogenic proton leak pathway. The importance of this 
facultative thermogenesis pathway was nicely demonstrated in UCP-3 -/- mice, which were almost 
completely refractory to the rise in body temperature induced by high doses of MDMA [92]. Moreover, 
these mice were protected from the potentially lethal effect, induced by the strong hyperthermic 
response to high doses of MDMA. 
 
II.5. Cognitive and behavioural impairments 
 MDMA abusers may suffer from neuropsychiatric deficits, including memory impairments [93-95], 
with recent studies suggesting that these deficits may persist after the cessation of abuse [95, 96]. Investigation 
of the behavioural and cognitive outcome of the (neurotoxic) effects of MDMA in mice may lead to a better 
understanding of the long-term consequences following the abuse of MDMA. Most of the knowledge regarding 
the mechanisms underlying cognitive impairments has been gathered through the use of pharmacological 
inhibitors. Up to now, only one study using genetically modified mice has evaluated the long-term cognitive 
consequences of MDMA administration. Cannabinoid CB1 receptors (CB1R) have been implicated in 
learning/memory, and are highly expressed in the hippocampus, a region of the brain believed to have an 
important function in certain forms of learning and memory. Using male CD1 wt and CB1R knockout (CB1R -/-) 
mice, Nawata and colleagues investigated the effect of withdrawal from repeated MDMA in an object 
recognition test [97]. Similar to what had been observed by others in rats [98-100], wt mice showed impaired 
recognition memory upon MDMA withdrawal. This impairment was not seen in CB1R -/- mice and in mice 
treated with a CB1R antagonist, suggesting that the activation of CB1Rs is involved in the appearance of 
cognitive impairment upon withdrawal from MDMA. As readily mentioned above, this effect may be related to 
the tight cross-talk that exists between the cannabinoid system (CB1R) and the serotonergic system [53]. 
 Another well-known effect following treatment of rodents with MDMA is a decrease in exploratory 
behaviour (typically evaluated as rearings and nose pokes). Interestingly, the effect of MDMA on this behaviour 
can be uncoupled from its stimulatory effect on locomotor activity. This was demonstrated in 5-HT1BR -/- mice, 
which show reduced MDMA hyperactivity, but maintain MDMA-suppressed exploratory behaviour [45]. This 
suggests that the exploratory suppression by MDMA does not involve the 5-HT1BR, which is in agreement with 
pharmacological studies in rats [101]. Kindlundh-Hogberg and colleagues investigated the effect of MDMA on 
the exploratory behaviour of C57/Bl6 mice overexpressing S100B, a glia-derived calcium-binding protein which 
is induced by serotonergic agents and has a role in neuronal plasticity [102]. Rearing activity of these mice was 
more strongly reduced than in wt controls following binge treatments with MDMA (3 x 5 mg/kg per day, every 7 
days, during 4 weeks). In addition, S100B overexpressing mice showed a stronger anxiolytic response following 
binge treatments with MDMA. Important to note in this context is that the differences seen between wt and 
S100B overexpressing mice were not seen following acute treatment, but only after repeated treatment. The 
mechanism underlying these differences remains to be elucidated.  
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 The 5-HT-releasing properties of MDMA have also been used in 5-HT1BR -/- mice to study habituation 
and prepulse inhibition (PPI) [103]. These measures of fundamental behavioural processes refer to respectively 
the decrease in response to repeated presentations of an initially novel and intense stimulus and to the reduction 
in startle amplitude when a weaker prestimulus (prepulse) precedes a strong startling stimulus. Deficits in PPI 
and habituation have been observed in a variety of neuropsychiatric disorders, including schizophrenia [104]. 
Using acoustic stimuli, MDMA (10 mg/kg) reduced the startle magnitude but had no effect on startle habituation, 
whereas it affected PPI in a strain dependent way, with decreased PPI in C57BL/6 mice and in the outbred strain 
ICR, but not in a 129/Sv substrain [105, 106]. This decrease in PPI following MDMA administration was still 
present in 5-HT1AR -/- mice, while 5-HT1BR -/- 129/Sv mice showed an increased PPI [105, 107]. These results 
suggest that, following MDMA-induced 5-HT release, the 5-HT1BR exerts a negative effect on PPI, which is not 
longer present in 5-HT1BR -/- mice (explaining the increase in PPI following MDMA administration in these 
mice). In summary, studies evaluating cognition (memory), exploratory behaviour and fundamental behavioural 
processes (sensorimotor gating) have shown that MDMA negatively impacts these processes. Studies using 
genetically modified mice have demonstrated the contribution of the serotonergic system (5-HT1BR) and the 
tightly linked cannabinoid system (CB1R) in these effects. 
 
II.6. Rewarding 
 MDMA has been shown to have reinforcing properties in humans [108, 109]. Murine, rat and monkey 
experimental models have also shown the rewarding properties of MDMA [109-116]. These models typically 
make use of conditioned place preference (CPP) tests (which evaluate the preference of an animal for a chamber 
in which it previously received MDMA) and operant intravenous self-administration tests. 
 Studies in 5-HT2BR -/- 129 Sv/PAS mice and 5-HTT -/- C57BL/6 mice have shown the requirement of 
the serotonergic system for the reinforcing effect of MDMA [50, 55]. In contrast to wt mice, 5-HT2BR -/- mice 
completely lacked a rewarding response (evaluated using CPP) following repeated administration of low dosages 
(10 mg/kg) of MDMA [55]. Importantly, 5-HT2BR -/- mice did not show the accumbal dopamine release 
observed in wt mice, with concomitant activation of extracellular regulated kinase (ERK) in dopamine D1 
receptor expressing neurons. Similarly, 5-HTT -/- mice lack the acquisition and maintenance of self-
administration of MDMA that is observed in a certain percentage of wt mice in an operant intravenous self-
administration test (though to a lesser extent than seen with cocaine) [50]. However, contrasting with the 
findings in the 5-HT2BR -/- mice, the ability of low-dose MDMA to increase extracellular levels of dopamine in 
the nucleus accumbens remained unaffected in the 5-HTT -/- mice. The lack of a rewarding effect in the 
presence of dopamine release in 5-HTT -/- mice suggests a specific involvement of the 5-HT system in 
mediating MDMA’s reinforcing effect. Hereby a requirement may exist for a fast change in 5-HT levels rather 
than for high absolute levels of extracellular 5-HT, which are readily present in 5-HTT -/- mice. Given these 
observations and given the fact that pharmacological approaches have also shown a role for the dopaminergic 
system in the reinforcing effect of MDMA [117], it is plausible that (disruption of) a delicate interplay between 
both systems is required for the MDMA reward. Consistent with this is the finding that unlike “low-dosage” 
MDMA, a high dosage (30 mg/kg) does lead to a rewarding response (and concomitant release of dopamine but 
not 5-HT) in 5-HT2BR -/- mice [55]. This different effect of MDMA, according to the dosage applied, may relate 
to the different pharmacological targets of MDMA, resulting in different behavioural effects. Thus, at low 
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dosage, MDMA may release 5-HT in a 5-HT2BR-dependent way, which may eventually lead to dopamine release 
in the nucleus accumbens. At high dosages, this dependence on 5-HT (and hence on 5-HT2BR) may be overcome, 
possibly because of a direct effect of MDMA on DAT. 
 Activation of CB1Rs has also been shown to be involved in the MDMA reinforcing effect. Similar to 
the failure of CB1R -/- mice to establish cocaine, morphine and ethanol self-administration to an extent as wt 
mice did [118-120], the CB1R -/- mice did not acquire the performance of MDMA self-administration [87]. 
However, these KO mice maintained their reaction to MDMA in a conditioned place preference test, similar to 
what had been observed in the response of these mice to cocaine [119, 121]. This loss of response of the CB1R -
/- mice in the self-administration test, but not the CPP test, suggests that the role played by the CB1R in the 
rewarding response does not lie in the primary rewarding response (scored by the CPP), but rather relies on brain 
circuits related to reward, motivation and long-term learning (scored by the self-administration test). This 
hypothesis fits with the finding that MDMA treatment did not induce differences in dopamine release between 
wt and CB1R -/- mice, with both groups showing a similar increase in dopamine extracellular levels in the 
nucleus accumbens, which is known to be involved in the acute rewarding effects of psychostimulants [122]. 
 A possible role for µ-opioid receptors in the rewarding properties of MDMA was investigated by 
Robledo et al. [123]. These authors applied the conditioning place preference paradigm onto µ-opioid receptor -
/- C57BL/6 mice, investigating whether these mice still had a preference for the compartment in which MDMA 
had been administered before. KO mice did not differ from wt, neither in terms of rewarding, nor in terms of 
MDMA-induced increase in extracellular dopamine in the nucleus accumbens. These results show that -opioid 
receptors are not necessary for the rewarding effects of MDMA.  Using a similar conditioning place preference 
test, Okuda and colleagues found that also histamine H3 receptor knockout C57BL/6J mice (H3R -/-) did not 
differ from wt mice in their rewarding response to MDMA [54].  
 
II.7. Various effects  
II.7.1. Anorectic properties of MDMA 
 In line with the well-known potent anorectic properties of 5-HT-releasers, MDMA is known to have 
appetite suppressant properties, as has been observed in e.g. dogs, rats and mice [124, 125]. In starved 129/Sv 
mice, a 10 mg/kg MDMA dosage provoked a biphasic feeding response, with initial 1 hour hypophagia, 
followed by hyperphagia during the next few hours [124]. This MDMA-induced delay in feeding response was 
maintained in 5-HT1BR -/- mice, which do not longer show the typical MDMA-induced hyperactivity [124]. Two 
studies have shown a role for 5HT2C and 5-HT4 receptors in the appetite suppressant effects of MDMA [124, 
126]. In a first study, the co-administration of RS102221, a 5-HT2CR antagonist, prevented both the hypophagic 
and hyperlocomotion effects of MDMA [124]. In another study, Jean et al. elegantly demonstrated that the 
anorectic effect of MDMA involves upregulation of the satiety factor CART (cocaine- and amphetamine 
regulated transcript) in the nucleus accumbens, via a cAMP/PKA signalling pathway, following activation of 5-
HT4Rs [126]. In the absence of either 5-HT4Rs (5-HT4R -/-) or CART upregulation (following knockdown via 
intracerebral injection of siRNA), there was (partial) inhibition of MDMA-induced hypophagia. Since 5-HT4R 
KO mice are less sensitive to stress, it is possible that the observed effects are the result of a diminished response 
to the “stressor” MDMA [126]. 
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II.7.2. Narcolepsy 
 Psychostimulants have a role in the treatment of narcolepsy, a chronic sleep disorder characterized by 
excessive daytime sleepiness and disturbed nocturnal sleep. A mouse model for narcolepsy, generated by 
knocking out orexin, has been shown to have remarkable similarities to  human narcolepsy, in which a 
dysfunctioning orexin/hypocretin system has been well-established now [127, 128]. As compared to wt mice, 
non-treated C57Bl/6 orexin deficient mice show a significantly reduced dopamine turnover and locomotor 
activity [129]. However, stimulation of locomotor activity following treatment of these knockout mice with 
MDMA was more prominent than in wt mice. Based upon the use of pharmacological 5-HT receptor inhibitors, a 
role for functional changes in 5-HT1A-, 5-HT2- and 5-HT7 receptors has been suggested to underlie this effect 
in orexin deficient mice [129]. 
 
II.7.3. Cardiovascular effects 
 Using KO mice, the group of Docherty set off to investigate the role of α2AAR (α2D in rodents) in 
MDMA’s vascular actions and its prejunctional actions in vas deferens [130, 131]. Reported cardiovascular 
actions of MDMA in humans include tachycardia and a (transient) rise in blood pressure (extensively described 
by K. Varner elsewhere in this issue)[108]. Similarly, MDMA administration (5 or 20 mg/kg) to C57Bl/6 mice 
resulted in an increased heart rate and an initial rise in arterial pressure (“pressor” response) [130]. In 
anaesthetised -but not in conscious- mice this initial pressor response is followed by a decrease in arterial 
pressure shortly thereafter (“depressor” response). MDMA-treated anaesthetised α2AAR -/- mice have a 
prolonged pressor response, with no depressor response occurring, at least not within the first 10 minutes after 
treatment. The absence of a depressor component in MDMA-treated anaesthetised α2AAR KO mice suggests that 
these receptors act to shorten the duration of the pressor response. The prejunctional actions of MDMA in vas 
deferens, however were unaffected in the α2AAR -/- mice [131]. Functional replacement of the α2AAR during 
development by another α2AR, possibly the α2CAR, may account for this observation.  
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III. Discussion & conclusion 
 
 Together, the use of advanced animal models, in particular genetically modified mice, has significantly 
contributed to our understanding of the mechanisms underlying the (toxic) effects of MDMA. These models, 
together with models under development, may help to answer remaining questions and may assist in the 
development of therapies, aimed at ameliorating potential neuronal damage and cognitive impairment following 
abuse of MDMA and related substances. Up to now, only constitutive mouse models have been described, 
expressing or lacking expression of a given gene readily from early development on. Obviously, a wealth of 
information on the role of specific neurotransmitter systems in confined brain regions or in well-defined 
neuronal subpopulations can be gained using (inducible) tissue-specific knockout, transgenic and rescue 
strategies. Such models with temporally and/or spatially regulated gene disruption or overexpression offer a 
significant advantage over the typically used pharmacological approach, because they allow the study of the role 
of a particular protein in a particular cell population. Recently, 5-HTT knockout rats have been generated [132], 
which, upon comparison with 5-HTT KO mice show overall major similarities in multiple neurobehavioral 
domains [133]. Given the fact that MDMA-induced neurotoxicity in rats better resembles that observed in 
humans, important information may be gained using these rats. Whereas only few genetically modified rat 
models are currently available (with not a single publication describing treatment with MDMA yet), recent 
progress in the field of developing genetically modified (knockout) rats by optimized and/or newly available 
technologies will likely lead to the development of many more strains in the coming years [134, 135]. 
Alternatively, local knockdown of particular genes in certain brain areas via RNAi (by injection of siRNA’s or 
viral vector-mediated) may be a complementary tool [136, 137]. The latter approach has, in addition to being 
less time-consuming, labour-intensive and expensive, the advantage that possible developmental compensation 
or adaptation may be overcome. However, a drawback is that complete knockdown in vivo is not feasible. 
Without a shadow of a doubt, the introduction of these advanced new tools and animal models -both mice and 
rats- will greatly progress our fundamental insights into the pharmacology and toxicity of MDMA in the 
upcoming decade. 
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